199 related articles for article (PubMed ID: 16394785)
21. Cyclooxygenase-inhibition enhances the effects of rSP-C surfactant therapy in a rat lavage model of acute respiratory distress syndrome (ARDS).
Häfner D; Ibrahim M; Wollin L; Germann PG
Exp Toxicol Pathol; 2003 Jul; 55(1):59-68. PubMed ID: 12940630
[TBL] [Abstract][Full Text] [Related]
22. A rat model of acute respiratory distress syndrome (ARDS) Part 2, influence of lavage volume, lavage repetition, and therapeutic treatment with rSP-C surfactant.
Häfner D; Germann PG
J Pharmacol Toxicol Methods; 1999; 41(2-3):97-106. PubMed ID: 10598681
[TBL] [Abstract][Full Text] [Related]
23. Surfactant replacement therapy for adult respiratory distress syndrome in children.
Evans DA; Wilmott RW; Whitsett JA
Pediatr Pulmonol; 1996 May; 21(5):328-36. PubMed ID: 8726159
[TBL] [Abstract][Full Text] [Related]
24. Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Members of the Mid-Atlantic Pediatric Critical Care Network.
Willson DF; Zaritsky A; Bauman LA; Dockery K; James RL; Conrad D; Craft H; Novotny WE; Egan EA; Dalton H
Crit Care Med; 1999 Jan; 27(1):188-95. PubMed ID: 9934915
[TBL] [Abstract][Full Text] [Related]
25. Three-dimensional model of surfactant replacement therapy.
Filoche M; Tai CF; Grotberg JB
Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9287-92. PubMed ID: 26170310
[TBL] [Abstract][Full Text] [Related]
26. Surfactant treatment for congenital heart disease patients with acute respiratory distress syndrome.
Alten JA; Borasino S; Pearce FB; Dabal RJ; Kirklin JK
Congenit Heart Dis; 2010; 5(6):624-8. PubMed ID: 21106025
[TBL] [Abstract][Full Text] [Related]
27. The Adult Calfactant in Acute Respiratory Distress Syndrome Trial.
Willson DF; Truwit JD; Conaway MR; Traul CS; Egan EE
Chest; 2015 Aug; 148(2):356-364. PubMed ID: 25855884
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of exogenous surfactant in HCL-induced lung injury.
Brackenbury AM; Puligandla PS; McCaig LA; Nikore V; Yao LJ; Veldhuizen RA; Lewis JF
Am J Respir Crit Care Med; 2001 Apr; 163(5):1135-42. PubMed ID: 11316649
[TBL] [Abstract][Full Text] [Related]
29. Surfactant: current and potential therapeutic application in infants and adults.
Lewis J; Veldhuizen RA
J Aerosol Med; 1996; 9(1):143-54. PubMed ID: 10160204
[TBL] [Abstract][Full Text] [Related]
30. The relationship of fluid administration to outcome in the pediatric calfactant in acute respiratory distress syndrome trial.
Willson DF; Thomas NJ; Tamburro R; Truemper E; Truwit J; Conaway M; Traul C; Egan EE;
Pediatr Crit Care Med; 2013 Sep; 14(7):666-72. PubMed ID: 23925143
[TBL] [Abstract][Full Text] [Related]
31. Exogenous surfactant treatments for neonatal respiratory distress syndrome and their potential role in the adult respiratory distress syndrome.
Merritt TA; Hallman M; Spragg R; Heldt GP; Gilliard N
Drugs; 1989 Oct; 38(4):591-611. PubMed ID: 2684594
[TBL] [Abstract][Full Text] [Related]
32. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome.
Spragg RG; Lewis JF; Walmrath HD; Johannigman J; Bellingan G; Laterre PF; Witte MC; Richards GA; Rippin G; Rathgeb F; Häfner D; Taut FJ; Seeger W
N Engl J Med; 2004 Aug; 351(9):884-92. PubMed ID: 15329426
[TBL] [Abstract][Full Text] [Related]
33. Surfactant therapy for acute respiratory distress in severe pediatric burn injury: a case series.
Sen S; Tung K; Palmieri T; Greenhalgh D
J Burn Care Res; 2012; 33(2):e88-91. PubMed ID: 22002204
[TBL] [Abstract][Full Text] [Related]
34. Surfactant replacement in neonatal and adult respiratory distress syndrome.
Robertson B
Eur J Anaesthesiol; 1984 Dec; 1(4):335-43. PubMed ID: 6549536
[TBL] [Abstract][Full Text] [Related]
35. Exogenous surfactant in acute respiratory distress syndrome: more is better.
Anzueto A
Eur Respir J; 2002 May; 19(5):787-9. PubMed ID: 12030713
[No Abstract] [Full Text] [Related]
36. [Surfactant replacement therapy increases life-span of patients with acute respiratory distress syndrome].
Potapov AL; Novikov NIu; Tumanskiĭ VA; Babanin AA
Klin Khir; 2013 Feb; (2):57-9. PubMed ID: 23705485
[TBL] [Abstract][Full Text] [Related]
37. Bovine surfactant therapy for patients with acute respiratory distress syndrome.
Gregory TJ; Steinberg KP; Spragg R; Gadek JE; Hyers TM; Longmore WJ; Moxley MA; Cai GZ; Hite RD; Smith RM; Hudson LD; Crim C; Newton P; Mitchell BR; Gold AJ
Am J Respir Crit Care Med; 1997 Apr; 155(4):1309-15. PubMed ID: 9105072
[TBL] [Abstract][Full Text] [Related]
38. Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat Respiratory Distress Syndrome: role of the different components in an efficient pulmonary surfactant.
Blanco O; Pérez-Gil J
Eur J Pharmacol; 2007 Jul; 568(1-3):1-15. PubMed ID: 17543939
[TBL] [Abstract][Full Text] [Related]
39. Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for RDS.
Stevens TP; Blennow M; Soll RF
Cochrane Database Syst Rev; 2002; (2):CD003063. PubMed ID: 12076469
[TBL] [Abstract][Full Text] [Related]
40. Comparison of exogenous surfactant therapy, mechanical ventilation with high end-expiratory pressure and partial liquid ventilation in a model of acute lung injury.
Hartog A; Vazquez de Anda GF; Gommers D; Kaisers U; Verbrugge SJ; Schnabel R; Lachmann B
Br J Anaesth; 1999 Jan; 82(1):81-6. PubMed ID: 10325841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
